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Abstract
This chapter focuses in the interrelationship between sleep and two neurode-
generative disorders: Amyotrophic Lateral Sclerosis [ALS] and Parkinson’s disease 
[PD]. Sleep disorders have deleterious effect on the quality of life and survival in 
these neurodegenerative disorders, while the reverse is also true where neurode-
generative disorders significantly impair the sleep, leading to a vast sleep complains 
that worsen the clinical course of these conditions. Other neurodegenerative 
disorders such as dementias, spinocerebellar ataxias, atypical parkinsonism, etc. 
will not be cover in this chapter.
Keywords: sleep, amyotrophic lateral sclerosis, hypoventilation, Parkinson’s disease, 
parkinsonism
1. Introduction
Given the effect of neuromuscular disease on respiratory muscle strength 
(including the diaphragm, upper airway and accessory muscles), it is an undeniable 
fact, that neuromuscular disease can cause disruption of sleep. In general, sleep 
disorders are underrecognized in this population, as their secondary effects can 
mimic symptoms of the underlying disease. Recognizing sleep-related disorders in 
patients with neuromuscular disease such as Amyotrophic Lateral Sclerosis (ALS) is 
of utmost importance, as they are potentially treatable problems and their correc-
tion can improve quality of life and even increase survival time [1].
ALS is an incurable neurodegenerative disorder of upper and lower motor 
neurons, which is characterized by degeneration of the corticospinal tracts, result-
ing in loss of motor neurons in the brain, brainstem and anterior horn cells of 
the spinal cord. Age of onset of disease is in the sixth decade of life and is usually 
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sporadic, though a minority of patients have familial disease. Numerous abnormali-
ties exist in cellular and molecular function in ALS, including protein aggregation, 
mitochondrial dysfunction, DNA and RNA processing and central nervous system 
inflammation [2].
The hallmark of clinical disease is the presence of both upper and lower motor 
neuron signs. Weakness in ALS starts as asymmetrical or focal, and then progresses 
to generalized weakness, ultimately affecting all skeletal muscles. Loss of motor 
neurons in the brainstem and spinal cord causes weakness of the pharyngeal, laryn-
geal, intercostal and diaphragmatic muscles. This predisposes patients with ALS to 
respiratory dysfunction (the physiology behind this to be detailed below). When 
respiratory dysfunction becomes severe, tracheostomy and permanent ventilation 
are required. From the time of the diagnosis the median survival time is 3 to 5 years. 
The most common cause of death in ALS is respiratory failure [3, 4].
There are two FDA approved medications for ALS. Riluzole was approved in 
1997 and provides a modest survival benefit of 3 months. A second medication, 
Edaravone, a free radical scavenger, was approved in 2017, but is only approved 
for use in ALS patients without respiratory insufficiency, and is controversial 
for clinical use due to its burdensome administration schedule and questionable 
clinical efficacy [5]. Numerous clinical drug trials have failed to demonstrate 
marked clinical benefit in ALS. However, provision of non-invasive ventilation 
has shown survival benefit in some ALS patients [6]. The dearth of effective 
treatment options for ALS underscores the importance of modifying those fac-
tors that optimize quality of life and extension of survival, particularly sleep and 
respiration.
2. Pathophysiology
Adequate involuntary ventilation is essential for effective sleep. The pathway 
by which voluntary ventilation occurs involves the cerebral cortex, brainstem and 
corticospinal tracts to motor neurons in the C3-C5 spinal segments which supply 
the phrenic nerve. The phrenic nerve innervates the diaphragm. In the state of 
wakefulness (in which both voluntary and involuntary ventilation persists), the 
diaphragm is the major inspiratory muscle and is assisted by accessory muscles. The 
accessory inspiratory muscles include the intercostals, trapezius, scalenes, sterno-
cleidomastoid and pectoralis major muscles. Involuntary or automatic breathing 
involves the respiratory centers in the brainstem (pons and medulla). This is the 
central respiratory drive. Oxygen and carbon dioxide levels sensed by chemore-
ceptors (peripheral and central) directly influence automatic breathing (which 
is then carried out through the spinal segments formerly mentioned innervating 
the diaphragm through the phrenic nerve). During non-REM sleep, muscle tone is 
decreased and during REM sleep muscle tone is almost completely lost. Automatic 
ventilation during sleep is almost completely dependent on the diaphragm (particu-
larly in REM sleep) therefore diaphragmatic dysfunction (such as that seen in ALS) 
can predispose to hypoventilation and nocturnal hypoxemia. The sensitivity of 
chemoreceptors is also reduced during sleep [1].
Effective sleep also depends on maintaining a patent upper airway. Patency of 
the upper airway is dependent on secondary muscles of respiration, which include 
the muscles of the pharynx. Pharyngeal muscle tone is maintained by trigeminal 
sensory afferents during inspiration, when negative pressure is generated. This 
prevents upper airway collapse. Weakness of pharyngeal muscles (such as in ALS) 
leaves one susceptible to airway collapse and the upper airway resistance seen in 
obstructive sleep apnea [1].
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3. Clinical features of sleep disturbances in amyotrophic lateral sclerosis
Sleep disorders are quite prevalent in patients with ALS, but often under-
reported, misdiagnosed, and undertreated. It has been shown that the onset of 
nocturnal breathing abnormalities often precedes the onset of overt daytime 
respiratory dysfunction [3]. A recent study showed that sleep disorders occur in 
70 percent of patients with ALS, where 65 percent have insomnia, 50 percent have 
sleep-breathing disorders including hypoventilation, and 85 percent suffer from 
night-time awakening related to ALS symptoms [7].
The most common form of sleep disturbance encountered in ALS is due to 
hypoventilation, rather than obstructive nocturnal events [8]. As ALS progresses, 
the involvement of the respiratory muscles is unavoidable; this results in nocturnal 
hypoventilation [9, 10]. Hypoventilation is the primary etiology of nocturnal 
oxygen desaturation (hypoxemia) in patients with ALS. This is due to bilateral 
phrenic nerve dysfunction resulting in diaphragmatic weakness or paralysis 
[11]. Nocturnal hypoventilation is first present when supine, as this is where the 
diaphragm is put at its worst mechanical disadvantage resulting in a drop in lung 
volumes [3, 12]. Diaphragmatic dysfunction in ALS is of particular concern in 
regard to sleep-disordered breathing as the diaphragm is the sole active respiratory 
muscle during REM sleep (where accessory and intercostal muscles are naturally 
inhibited) [13]. For this reason, nocturnal hypoventilation is especially worse 
during REM sleep [12, 14].
Quality of sleep in those without advanced disease can be normal (although 
quality of life is impacted by respiratory muscle weakness) [11]. As the disease pro-
gresses fragmentation of stage N3 of sleep occurs due to loss of circadian rhythms 
[13]. All stages of sleep are eventually affected resulting in daytime hypercapnia 
which is defined as an elevated CO2 > 45 mm Hg. Hypoxemia and hypercapnia 
result from respiratory failure and the hypoventilation syndrome caused by restric-
tive thoracic disease from weakness of respiratory muscles. This hypoventilation 
syndrome results in a decrease in sensitivity of chemoreceptors due to chronic 
hypercapnia [15]. Hypoventilation is further complicated with the co-existence of 
sleep-breathing disorders.
Sleep-breathing disorders are common in ALS. Oropharyngeal weakness affect-
ing dilatory muscles leads to obstructive sleep apnea that presents like in non-ALS 
OSA patients with snoring, snorting, apneas, and frequent nocturnal arousals [16]. 
In a study of 18 patients with ALS, it was found on polysomnography that total 
sleep time was decreased, and frequency of sleep-disordered breathing and arous-
als were higher than in age-matched controls. Eight of these patients were found 
to have periods of hypoventilation (most often during REM sleep). There were no 
recorded apneas. Bulbar involvement did not show a significant association with 
degree of sleep-disordered breathing [2]. Bulbar weakness does however predis-
pose to obstructive sleep apnea due to weakness of tongue protrusion and palatal 
control. Bulbar weakness is also associated with increased secretions and weak 
cough [13]. That being said, since patients with bulbar ALS have tongue atrophy, 
they have less prevalence of OSA [17, 18]. Central sleep apneas in ALS patients may 
result from central motor neuron impairment, though they are less frequent than 
OSA [15].
Particular importance should be placed on addressing respiratory muscle 
weakness (hypoventilation) rather than the number of apneas or hypopneas on 
polysomnography in ALS patients [11]. OSA is common in ALS and if untreated 
shortens the survival of ALS patients [3, 12]. Non-invasive positive pressure 
ventilation can prolong time to tracheostomy and provide benefit in regard to 
quality of life in the setting of respiratory muscle weakness and sleep-disordered 
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breathing [11]. Therefore, when OSA is suspected a polysomnogram should be 
requested to confirm its diagnosis.
In regard to the effects of sleep-disordered breathing on quality of life, ALS 
patients often complain of excessive daytime sleepiness resulting from nocturnal 
sleep fragmentation and insomnia. Nocturnal hypoventilation results in orthop-
nea, morning headaches, excessive daytime sleepiness, and cognitive dysfunction 
[12, 17]. A study showed the most common nocturnal complaints in ALS patients 
were nocturia, sleep fragmentation, and cramps (each seen in about half of the 
patients) [19]. Table 1 shows the common sleep disturbances seen in ALS.
Nocturnal restlessness, sleep fragmentation with multiple awakening, snoring, 
and apneas leads to excessive daytime sleepiness, difficulties to arouse in the morn-
ing, difficulties to arouse from sleep, cognitive problems and poor work perfor-
mance. In severe cases when insomnia and sleep continuity is severely impaired 
patients develop lethargy, cyanosis, early morning headaches, nausea and vomiting 
and leg edema. Table 2 shows the most common sleep features in ALS patients.
Patients with ALS suffer from other conditions that also affect the sleep such 
as restless leg syndrome (RLS), REM-sleep behavior disorder (RBD), cramps, 
immobility-associated discomfort, pain, depression-related sleep disorders and 
dementia-related sleep disorders which may affect the sleep continuity. Even 
patients newly diagnosed with ALS have shown poor sleep quality related to depres-
sion and poor nocturnal mobility [12, 17, 19].
There are important secondary cardiopulmonary effects of chronic nocturnal 
hypoxemia that should not be overlooked. These include pulmonary hyperten-
sion, right heart failure and arrhythmia. There is also an increased risk of stroke, 
myocardial infarction and lethal cardiac arrhythmias. This highlights the critical 























WASO: wake after sleep onset.
Table 2. 







Sleep disturbances in ALS.
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need to diagnose and treat sleep-disordered breathing early particular in ALS where 
lifespan is devastatingly shortened [20].
4. Diagnosis
Essential to the identification of ALS patients with sleep abnormalities is main-
taining a high index of suspicion and taking a detailed sleep history. This ideally 
takes place with a family member or caregiver present (or anyone who may share a 
bed with the patient). This second party can provide history regarding the patient’s 
behaviors during sleep and functioning in the daytime (some of which the patient 
himself/herself may not be aware of). Specific questions regarding the presence of 
excessive daytime sleepiness, cognitive dysfunction, orthopnea, apneas and snoring 
are essential. Frequent awakenings, snoring and choking are clues for suspecting 
obstructive sleep apnea. Nocturnal orthopnea is often an early sign of respiratory 
dysfunction causing hypoventilation. Commonly used screening tools for sleep dis-
orders include STOP-BANG, Epworth Sleepiness Scale and Pittsburgh Sleep Quality 
Index Scale [3]. All patients with respiratory dysfunction or bulbar weakness should 
be screened for sleep disorders. Close attention should be placed on examining 
for signs of respiratory dysfunction such as accessory muscle use (particularly 
when supine). Increased work of breathing can result in weight loss and cachexia. 
Patients with bulbar dysfunction progressively develop changes in their voice, dif-
ficulty clearing secretions, weak cough and difficulty swallowing [21].
There are multiple modalities that can be utilized in the diagnostic evaluation of 
respiratory muscle weakness and sleep disorders in ALS. The use of more than one 
modality increases the precision and accuracy of the diagnosis and prevents over- or 
underestimation of respiratory muscle strength [20]. Table 3 outlines the different 
laboratory investigations used to diagnose sleep disorders in ALS.
If hypoventilation is suspected, then spirometry should be requested. Clinical 
indicators include excessive daytime sleepiness, morning headaches, frequent noctur-
nal waking, and vivid dreams [22]. Forced vital capacity (FVC) has long been used to 
predict survival and disease progression in ALS patients. Faster progression of disease 
has been associated with FVC < 75 percent of predicted value. A more accurate 
measure of weakness of the diaphragm is supine FVC however this can be difficult to 
evaluate [21, 22]. The difference between standing and supine FVC correlates with 
orthopnea and a fall from sitting to supine >20 percent has a sensitivity of 90 percent 
for identifying diaphragmatic weakness [12], whereas sitting FVC < 50 percent has 
only a sensitivity of 58 percent. Despite wide availability in obtaining FVC it is not as 
sensitive for early respiratory dysfunction and values may be inaccurate in patients 
with bulbar dysfunction who cannot maintain a tight seal on the mouth piece [21].
Arterial Blood Gas (ABG)
Pulmonary Function Tests
• Sitting and supine forced vital capacity (FVC)
• Maximal inspiratory pressure (MIP)
• Maximal expiratory pressure (MEP)




Investigations commonly used to detect sleep disorders in amyotrophic lateral sclerosis.
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The sniff nasal transdiaphragmatic pressure (SNIP) is a strong predictor of 
diaphragmatic muscle strength. It is a non-invasive inspiratory volitional test. It 
can also be used to monitor progression of disease [21]. In addition, SNIP testing is 
not limited by the requirement of securing an adequate seal over the instrument’s 
mouthpiece, rendering it advantageous for evaluation of patients with prominent 
cranio-bulbar weakness. The sniff test has a sensitivity of 97 percent for a sniff 
value <40 cm H2O for predicting six-month mortality, compared to 58 percent 
sensitivity of VC < 50 percent [23, 24]. SNIP value <40 cm H2O is strongly corre-
lated with nocturnal hypoxemia in ALS patients [24] (see Figure 1). This predictive 
value for nocturnal hypoxemia was not seen with other measures of respiratory 
sufficiency such as MIP and FVC [24].
Maximal inspiratory pressure (MIP) and maximal expiratory pressures (MEP) 
are useful for predicting early respiratory muscle weakness. MIP is done by inspir-
ing from residual lung volume. MEP is done by having the patient maximally expire 
against a closed airway. MIP > 80 cm H2O or MEP > 90 cm H2O excludes significant 
respiratory muscle weakness [21]. MIP < 40 cmH2O also identifies people at risk 
of hypoventilation. This test may underestimate the degree of respiratory muscle 
weakness as it involves a mouthpiece and those with facial or bulbar weakness 
may not form a tight seal around it. This test does require effort on the part of the 
patient [21].
Nocturnal pulse oximetry and capnography can also be used for screening for 
hypoventilation. Nocturnal pulse oximetry is often the first test ordered when 
sleep disturbance is suspected as it is inexpensive and non-invasive [20]. Nocturnal 
desaturation <90 percent for >5–10 percent of the time may suggest hypoventila-
tion [23]. A nocturnal desaturation to less than 90 percent for one minute is also 
helpful to diagnose hypoventilation [22]. Patterns seen in early disease suggestive 
of hypoventilation are cyclical desaturations with low baseline oxygen saturation. 
This pattern is also seen in COPD or interstitial lung disease and nocturnal pulse 
oximetry cannot distinguish between these conditions. There are also some techni-
cal problems with nocturnal pulse oximetry as the oximeter can become dislodged 
or readings can be inaccurate in the setting of anemia. [20] Capnography is utilized 
Figure 1. 
Scatterplot of the proportion of the night spent with nocturnal hypoxemia (defined as oxygen saturation < 90 
percent) in ALS patients with SNIF <40 cm H2O compared to those with SNIF >40 cmH2O [24].
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in diagnosing hypoventilation by measuring a nocturnal transcutaneous carbon 
dioxide [PtcC02] increment of >10 mm Hg above 50 mm Hg for >10 min. This is 
performed with simultaneous pulse oximetry recording to compensate for possible 
aberrant valuates seen at times with PtCO2 [25].
Nocturnal and daytime arterial blood gases (ABG) is another tool that can be used 
to predict nocturnal hypoventilation resulting in hypoxia (PaO2 < 60 mm Hg) and 
hypercapnia (PaCO2 > 45 mm Hg). Nocturnal hypoventilation is suggested by an 
increase of PaCO2 by 10 mm Hg when comparing nocturnal to daytime values. This 
method is more invasive, and disparities can sometimes only be seen late in the dis-
ease [20]. Hypoventilation can also be diagnosed by ABG with hypercapnia defined as 
a cut off of PCO2 > 45 mm Hg while resting in a seated position for 15 min [26].
In-laboratory overnight polysomnography is the gold standard for the diagnosis 
of hypoventilation and OSA. At home tests are not recommended for patients with 
neuromuscular disease as these are limited studies. The standard polysomnogram 
consists of at least 3 electroencephalography (EEG) channels, chin and leg electro-
myography (EMG), 2 eye (electrooculogram) leads, effort channels, flow channels, 
electrocardiography and SaO2. This allows for tracking and monitoring the stages 
of sleep, SaO2 abnormalities and any abnormal movements [20]. Polysomnography 
[PSG] with capnography [transcutaneous PCO2] detects sleep-related hypoventila-
tion [PCO2 increment more than 10 mmHg during sleep versus wakefulness, espe-
cially during REM] and is more sensitive than oximetry. One third of the patients 
with confirmed sleep hypoventilation have normal oxygenation [12, 19]. Using 
PSG, the etiologies of sleep disturbances can be distinguished using analysis of this 
multimodal test and patterns of SaO2 abnormalities. This allows for recognition of 
hypoxemia that is event related (obstructive sleep apnea) or due to hypoventilation 
(or a combination of both) [20].
The measurement of diaphragmatic thickening using ultrasound is a new 
developing technique that predicts hypoventilation, though no cut off value has 
been established [19].
5. Treatment
Basic sleep hygiene should always be emphasized with the patient and family as 
the usefulness of these interventions is often overlooked. Treatment of comorbid 
conditions that may be contributing to sleep disorders or fatigue such as hypothy-
roidism, depression or obesity should also be addressed.
The mainstay of treatment of sleep-disordered breathing in ALS is through 
assistance of the weakened respiratory muscles with positive upper airway pressur-
ization [20]. Non-invasive positive pressure upper airway ventilation [NIV]  
should be considered when hypoventilation is clinically suspected and confirmed 
with spirometry [19]. Practice parameters recommend initiation of NIV when SNIP 
falls below 40 cm H2O, FVC < 50%, or in the setting of abnormal nocturnal  
oximetry [22].
It is well established, that NIV improves symptoms of sleep disturbance, quality 
of life and cognitive function and is primarily indicated in sleep-disordered breath-
ing and inspiratory muscle dysfunction. NIV may also prolong tracheostomy -free 
survival [19]. Studies have shown a slower rate of decline of FVC and pulmonary 
function with use of NIV in ALS patients. Benefit in survival correlated with at 
least 4 hours of NIV use at night [20]. Most patients with ALS will need NIV at 
first while sleeping, but later as symptoms progress with more dyspnea and hyper-
capnia/hypoxemia-related-symptoms NIV will be required for longer periods of 
ventilation and then continuously [12, 19]. They are at first treated with NIV and 
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finally with tracheostomy with total ventilator support, if elected by the patient, or 
with supportive measures in hospice until death.
The aim of NIV is normalization of hypercapnia, hypoxia, and the apnea-
hypopnea index. This results in improvement of the sleep architecture and pro-
longed survival up to one year [19]. NIV is divided in pressure-assisted control 
where partial pressure is provided and volume-assisted control where the patient 
receives a predefined gas volume. Volume-assisted control has the advantage of 
overcoming airflow obstruction and being effective in obstructive events, but it 
has the disadvantage of an uncomfortable feeling caused by the ventilation and no 
compensation for leaks [27]. The pressure assisted control is more comfortable and 
it compensates for leaks. One study showed greater survival with pressure-assisted 
over volume-assisted ventilation [28]. NIV using nasal ventilation is preferred 
because it allows speech and induces a lower rate of OSA. Patients require close 
surveillance in the first few days of use to determine proper the settings and then 
monthly or quarterly evaluations thereafter. NIV failure is most commonly caused 
by leaks [29] and the coexistence of untreated OSA that increases mortality.
Bronchial congestion caused by weak coughing and excessive sialorrhea may also 
cause failure of NIV therapy. Sialorrhea may be treated with drugs [atropine, scopol-
amine, belladone tincture], and if these drugs fail with salivary glands radiation; Botox 
injections are not recommended. Keeping the head up to avoid supine position, cervi-
cal collars, or mandibular advancement may also be helpful in addition to NIV [19].
To assist cough, mechanical insufflation-exsufflation (MI-E) devices can be 
prescribed to patients in order to clear airway secretions and prevent development 
of pneumonia. These devices administer pressure (both positive and negative, as 
might be done in a voluntary cough) artificially and can be used via face mask or 
tracheostomy [30].
It is important to mention, that bulbar dysfunction poses some management 
challenges in regard to the use of NIV. Compliance with use of NIV in these patients is 
lower due to decreased tolerance. As previously mentioned, hypersalivation in these 
patients worsens prognosis with NIV and requires symptomatic treatment. The initial 
study that showed increased survival with use of NIV [31] in patients with ALS did 
not show benefit in patients with severe bulbar symptoms however more recent stud-
ies have contradicted this. For this reason, treating symptoms that limit NIV usage in 
these patients is essential. Full face masks rather than the nasal mask are necessary for 
patients with bulbar dysfunction due to incomplete mouth closure [32].
6. Sleep disorders in Parkinson disease
Parkinson Disease [PD] is the second most common neurodegenerative disorder 
after Alzheimer’s disease [33]. PD occurs as a result of chronic, progressive decrease 
in dopamine levels of the substantia nigra, secondary to loss of dopaminergic neurons 
in the pars compacta and the occurrence of Lewy bodies in the cytoplasm of remain-
ing neurons [34]. It is primarily diagnosed clinically and patients may present with 
the characteristic motor deficits, which include the resting tremor, bradykinesia, 
rigidity and postural instability. However, most will have both motor and nonmotor 
symptoms. The nonmotor symptoms cause disturbances, which affect sleep, mood, 
cognition, sensation and autonomic function. Among the nonmotor symptoms in PD, 
sleep disorders are second in frequency only to neuropsychiatric disorders [35].
It is estimated that between 55 to 80 percent of PD patients suffer from sleep 
disorders [SD] [36, 37]. Sleep can be affected in a multitude of ways with the most 
common SD displayed in Table 4. Some disturbances will precede the disease, while 
others are indicators of disease progression. In many cases, more than one sleep 
9
The Relationship between Amyotrophic Lateral Sclerosis and Parkinson’s Disease and Sleep…
DOI: http://dx.doi.org/10.5772/intechopen.98934
disorder may coexist in the same patient. Poor sleep, particularly if chronic, will 
have an impact on daily activities causing excessive daytime sleepiness [EDS] and 
sleep attacks [SA]. The neurodegenerative process caused by PD itself will exac-
erbate daily drowsiness, as well as certain medications [38]. Therefore, a detailed 
sleep history in a patient with PD is imperative to identify symptoms in order to 
treat accordingly and monitor their progression. There is evidence to suggest that 
improving a patient’s quality of sleep not only will improve their quality of life, but 
can also lead in an improvement of their motor symptoms.
Another important consideration for patients with bradykinesia and rigidity, 
who may have trouble turning in bed at night or getting to the bathroom - is using 
an extended release formulations as their last dose of the day that might disrupt 
their sleep or, even worse, lead to falls.
Two validated scales were created to assess the severity of the impact of PD 
[Parkinson Disease Sleep Scale (PDSS) and Scales for Outcome in PD Sleep 
[SCOPA-S] [39, 40].
7. Sleep architecture changes in PD
Patients with PD often have many sleep architecture changes, the most common 
ones are shown in Table 5. The sleep architecture abnormalities include intrinsic 
brain changes caused by the underlying neurodegenerative disorder, co-existent 
sleep disorders, nocturnal motor symptoms, and dopaminergic medications.
8. Nocturnal sleep disorders
8.1 Insomnia
Insomnia affects approximately 50 to 60% of patients with PD, making it the 
most common sleep disorder and perhaps the most complex to treat given its 
multifaceted basis [42]. When it lasts for more than three months, it is considered 
chronic insomnia [43].
It can be further classified into the following patterns:
• Sleep-onset insomnia: when the patient has difficulty falling asleep
• Sleep-maintenance insomnia, also referred as sleep fragmentation: when the 
patient has difficulty staying asleep
• Terminal insomnia: when the patient awakens involuntarily earlier than usual





Periodic limb movements of sleep
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The most common insomnia is sleep-maintenance insomnia seen in 80 percent 
of patient with PD, whereas sleep onset and terminal insomnia are seen in 18 percent 
and 40 percent of the PD patients, respectively [36, 37, 44, 45]. Insomnia is more 
prevalent in women, those with longer PD duration, and those with depression or 
anxiety. The causes of insomnia is multifactorial and includes the neurodegenera-
tive process of PD itself, co-morbid sleep disorders, nocturia, cramps, limitation in 
mobility (i.e. difficulty turning in bed), early morning leg dystonia, pain, confusion, 
urinary dysfunction, sleep breathing disorders [SBD], and drugs [36, 42, 45, 46, 47]. 
Circadian rhythm disorders and psychiatric disorders [depression, anxiety, halluci-
nations, etc.] may also contribute in the genesis of insomnia [45–47].
Before deciding on a treatment option for insomnia, it is important to establish 
the specific pattern of insomnia and other risk factors that may be contributing to 
the condition. For example, addressing motor symptoms and/or obstructive sleep 
apnea may significantly improve insomnia therefore reducing or even eliminating 
the need for pharmacological interventions.
Almost half of patients with PD take medications for insomnia [36, 37, 42]. The 
use of levodopa-carbidopa controlled release [LD-CD] at bedtime may reduce motor 
bradykinesia/akinesia with improvement in total sleep time [48]. Dopamine agonists 
[DA] such as ropinirole-24 hour prolonged release (2-24 mg/day) [49], pramipexole 
(up to 4.5 mg/day) and transdermal rotigotine patch (up to 16 mg/day) [50] can be 
used as adjuncts to LD-CD. This combination has shown to improve both nocturnal 
motor activity and sleep symptoms. Two trials with transdermal rotigotine patch 
demonstrated improvement not only nocturnal motor symptoms but also wake time 
after sleep onset [WASO], nocturia, pain, RLS with reduced daily sleep episodes and 
overall improved quality of life in PD patients [51, 52]. MAO-inhibitor rasagiline has 
shown to improve total sleep time and reduce sleep latency when used in combina-
tion with LD-CD compare to when LD-CD is used alone [53]. Rasagiline’s beneficial 
effects on insomnia are likely related to an increment in melatonin levels.
After motor impairment and co-existent sleep disorders are identified and 
treated, insomnia can further be managed with cognitive behavioral therapy 
utilizing sleep hygiene techniques, stimulus control, sleep restriction, relaxation 
techniques, and cognitive therapy [53, 54]. Soporific drugs such as eszopiclone, zol-
pidem, doxepin, trazodone, ramelteon, and melatonin have been used with various 
success in the therapy of insomnia in PD patients [44]. Melatonin at very high doses 
(50 mg) at bedtime was compared with 5 mg/day at the bedtime in the treatment 
of insomnia in PD patients. Melatonin 50 mg dose showed a statistical significant 
improvement in total sleep time compared to lower doses, however melatonin at 
5 mg improved subjective sleep disturbance, sleep quantity, and daytime drowsi-
ness compared to placebo. Melatonin may be associated with morning headaches, 
hallucination, and daily drowsiness [55].








WASO: wake after sleep onset. N3; NREM slow waves stage [41].
Table 5. 
Sleep architecture in PD.
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8.2 Nocturia
Nocturia is defined as an increase in the frequency of nocturnal urination. 
About one third of PD patients suffer from nocturia [56]. Nocturia in PD is most 
likely a result of autonomic dysfunction caused by detrusor hyperreflexia from lack 
of dopamine which decreases the inhibition of micturition. However, it is important 
to rule out secondary organic causes of nocturia (such as urinary tract infections, 
prostrate disorders, anxiety, congestive heart failure, etc.) before altering anti-
Parkinson medication doses [45, 48].
Subcutaneous apomorphine at a dose of 3-8 mg at bedtime has been used to treat 
nocturia as it reduces the hyperreflexia in the detrusor muscles [57]. Rasagiline at 
a dose of 1 mg/day can increase bladder capacity and decreases residual volume 
[58]. Intranasal desmopressin and botulinum toxins in the detrusor muscles may 
be beneficial. Anticholinergic drugs [oxybutynin, solifenacin, darifenacin, toltero-
dine], can potentially help with nocturia, although the side effects of these drugs 
(drowsiness and cognitive impairment) might be an impediment [35].
8.3 Restless leg syndrome
Restless leg syndrome [RLS] is a sensorimotor disorder characterized by an 
unpleasant leg sensation associated with an urge to move the legs, relieved by leg 
movement, worsen by inactivity and worse at night [43]. RLS is seen in about 20% 
of patients with PD, which is a higher rate than in the general population [59]. 
Primary RLS is a genetic disorder, whereas secondary RLS results from other condi-
tions such as renal disease, iron deficiency, co-existence of neuropathies, medica-
tions, etc. [43, 60]. PD patients who develop RLS tend to have later PD onset, poor 
sleep quality and more cardiovascular and anxiety disorders [45, 59]. RLS need to 
be differentiated from common complain seen in PD patients such as uncomfort-
able nocturnal motor symptoms secondary to immobility, akathisia and dystonia. 
The treatment of RLS in PD patients is similar to the treatment for non-PD patients. 
Identify and treat any underlying secondary causes of RLS first. Iron supplemen-
tation is required when ferritin levels are below 50 microg/ml. Antidepressants 
may worsen RLS symptoms therefore adjustment in dosage or replacement with 
bupropion with dopaminergic effect is warranted [60, 61]. Antidopaminergic 
and antihistaminic medications can also worsen RLS [45]. L-dopa-carbidopa is 
no longer recommended to treat RLS due to the high risk of augmentation (treat-
ment complication from dopaminergic drug with worsening of the RLS symptoms 
[45, 60, 61]. Dopamine agonists (ropinirole, pramipexole, transdermal rotigotine 
patches) and GABAergic products (pregabalin, enacarbil, gabapentin) can be used 
as first line of therapy. The latter being particularly useful in patients with a coexis-
tent neuropathic pain [60, 61]. Other drugs as clonazepam and opioids may be used 
to induce sleep and treat pain, respectively. New devices that apply pressure to the 
legs may also relieve RLS symptoms [62].
8.4 Periodic leg moment of sleep
Periodic leg moment of the sleep [PLMS] is a sleep disorder characterized by 
repetitive leg movements while patient is asleep that result in sleep fragmentation 
and daily drowsiness. Whereas the diagnosis of RLS is clinical the diagnosis of PLMS 
is polysomnographic. A PLMS index [leg movements per hour of sleep] of 15 or 
more is considerate abnormal [43]. PLMS is seen in 80% of patients with RLS [43] 
and the incidence of PLMS is 30–80% of patients with Parkinson disease [45, 63]. 
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Age and dopamine loss may contribute to PLMS [64]. The mainstay treatment for 
PLM is the use of dopamine agonists [65].
8.5 REM behavior disorder
REM Behavior Disorder (RBD) is a REM-parasomnia characterized by the ability 
of the patient to reenact the content of his dreams with complex and violent motor 
behaviors which varies from vocalization, throwing punches, kicking, flailing, 
screaming, to jumping from the bed and running. This can cause injuries to the 
patient and/or to the bed partners [43]. RBD is commonly seen in PD [66] and is 
more prevalent in the second half of the night when REM sleep occurs [43]. Studies 
have demonstrated that RBD may manifest years prior to the development of PD 
symptoms with an estimated 75–90% of RBD patients developing PD after 10 to 
14 years from onset [43]. RBD may precede the onset of others alpha-synucleinopa-
thies such as Lewy Body dementia and multiple system atrophy [43]. RBD should be 
considered in patients presenting with history of “acting out their dreams or motor 
activation while sleeping” and confirm it with video polysomnography, though not 
require for its diagnosis. Creating a safe sleeping environment is the first step in 
management. This condition responds to low dose of clonazepam [0.25-2 mg qhs]. 
Clonazepam improves total sleep time, sleep efficiency, increase in NREM sleep, 
and decrease WASO [67, 68]. However, this medication was associated with seda-
tion, cognitive deficits, and increments in falls [45]. Melatonin 3 to 12 mg at night or 
at higher doses is also helpful in RBD and can be used with dementia and obstruc-
tive sleep apnea where clonazepam is not recommended. Melatonin may be used as 
solo or co-adjuvant therapy for insomnia and at high doses may be associated with 
morning headaches, sedation, or delusion/hallucinations [45, 69]. Patients who 
failed clonazepam and melatonin may respond to rivastigmine [70] or ramelteon 
[71] at night.
8.6 Sleep-breathing disorders
Obstructive sleep apnea (OSA) is the most common sleep breathing disorder 
(SBD). Other forms of SBDs are also seen in PD such as snoring, central and mixed 
apneas [43]. OSA is characterized by intermittent and repetitive events of pharyn-
geal airway collapse with complete upper airway obstruction (apnea) or partial 
upper airway obstruction (hypopneas) during sleep, especially during REM sleep 
when the effect of the atonia is more pronounced. Patients present with nocturnal 
snoring, snorting, sleep fragmentation, insomnia, and daily consequences of 
daytime sleepiness, fatigue, poor concentration, poor memory, and mood changes. 
If severe, it is associated with sleep attacks [spells of sudden sleepiness] [43]. The 
prevalence of OSA in PD varies between 20–60% depending on the methodology 
used to score respiratory events [45] and according to two recent studies it is more 
common in PD patients than in the general population [72, 73]. An additional study 
showed that SBDs are also more common in other forms of parkinsonism such as 
vascular parkinsonism than controls [74]. From all forms of SBDs [snoring, central 
sleep apneas and obstructive sleep apneas] OSA is the most common form in PD 
[74]. This is likely related to multiple factors seen in patients with PD: most PD 
patients are elders [advanced age is a risk factor for OSA], PD present with auto-
nomic dysfunction [autonomic dysfunction increases the risk for OSA], PD patients 
share loss of motor neurons from brainstem involved in respiration [reduced respi-
ratory drive] and control oropharyngeal muscles [fluctuating respiratory muscle 
coordination increases risk for OSA], PD patients have restrictive lung disease 
caused by chest wall rigidity and upper airway abnormalities as shown spirometry 
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abnormalities in up 65% patients with PD [75]which increased the risk for upper 
airway obstruction [42, 74]. The diagnosis of OSA is suspected through history and 
specific screening questionnaires such as STOP-BANG and Berlin’s questionnaire. In 
PD, STOP-BANG has a high sensitivity, but low specificity in the diagnosis of OSA, 
whereas the Berlin’s Questionnaire has a higher sensitivity in the diagnose of PD, 
but it sensitivity declines as the severity of PD declines [76]. And it is confirmed 
with polysomnography at a sleep center or level III portable monitoring at home [77, 
78]. OSA may worsen PD as it worsens sleep fragmentation and causes intermittent 
hypoxia [45, 79, 80] which is associated with worsening in the cognitive function 
[81, 82]. Sleep disorders are considered one of the most disabling of the non-motor 
symptoms of PD [83]. The treatment of OSA with PD is the same than in patients 
without PD: body weight loss, positional therapy, continuous positive airway 
pressure (CPAP), and surgery [45, 84]. The cognitive impairment often reported in 
patient with Parkinson disease [81, 82] also improves with positive airway pressure 
therapy [85].
8.7 Circadian rhythm disorder
Circadian rhythm disorders (CRD) are implicated in the pathophysiology of PD 
[86], but their real prevalence in PD patients remains unknown [87]. Motor and 
non-motor features [autonomic function, visual performance, sleep-awake cycles, 
and response to dopaminergic drugs] experienced a diurnal fluctuation from the 
circadian system [88]. Dopamine is an intermediary of light providing input to the 
retinal circadian clock which provides a direct input to the suprachiasmatic nuclei 
(SCN). Thereby, via retinal dopamine-containing amacrine cells, information is 
conveyed across a series of clock genes that control the circadian rhythm. Dopamine 
deficiency, seen in Parkinson disease, affects specific clock genes (dysregulation 
of Bmal gene expression) resulting in dysfunction of the central sleep–wake cycle 
control [86, 87]. Studies using actigraphy to record times of wrist motor activity 
[wakefulness] and times of motor inactivity [sleepiness] showed lower peaks of 
physical activity during rest time and higher levels of activity at night compared 
with control [89, 90]. Motor symptoms in Parkinson disease worsen in the after-
noon and evening in stable patients and patients with wearing off [advanced PD] 
indicating that the response to dopaminergic drugs declines throughout the daytime 
[91]. This decrease in diurnal activity and increase in nocturnal activity observed in 
PD patients is influenced by dopaminergic drugs [86]. A variability in the phar-
macokinetics of levodopa, i.e. faster during daytime and while standing compared 
with being supine at night, play the role in levodopa variability [92]. Patient with 
PD with hallucinations show more fragmentation of the rest activity with more 
unpredictability in the circadian pattern [93].
Autonomic dysfunction, a common feature in PD, also follows a circadian 
pattern with a nocturnal blood pressure reversal pattern i.e. blood pressure equal or 
higher than daytime blood pressure as demonstrated in most of the patients in one 
study [94]. An attenuation of sympathetic nervous system activity in PD patients 
was demonstrated by a heart rate variability study where power spectral analysis 
using a 24-hour ambulatory EKG revealed a decrease in total frequency component 
and low frequency/high frequency ratio [86, 94]. Studies in PD patients have shown 
a reduction in core body temperature. This reduction in core temperature correlated 
with higher rates of self-reported RBD symptoms, reduction in percentage of REM 
sleep, and prolonged latency compared with controls [95].
Hormonal changes are also affected by circadian rhythms in PD. PD patients 
have shown elevated serum cortisol levels and reduced serum melatonin levels 
compared with controls [96, 97]. Furthermore, melatonin diurnal fluctuations are 
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blunted in PD patients [98] which correlates with the self-reported symptoms of 
EDS [97]. The amplitude in melatonin decreases and melatonin phase advanced 
in PD treated patients compared with non-treated patients indicating that as PD 
progresses melatonin decreases with a phase advancement [99]. Dopamine drugs 
affect the regulation of melatonin circadian pattern and sleep onset patients in PD 
patients [100].
Circadian rhythm changes affect also visual performance in PD [101] most likely 
caused by impairment in retinal dopamine content that follows a circadian rhythm 
independent of light/dark cycles [102] Dopamine agonists may regulate the rhyth-
mic expression of melanopsin in retina ganglion cells [88].
In summery the causes of CRD in PD are multifactorial and some are included 
below list:
• Disorders of the sleep-awake neuronal circuity controlling the circa-
dian rhythm.
• Hypothalamic dysregulation with a decline of the SCN that lead to reduction in 
melatonin production and sleep-awake disruption.
• Dysregulation of the genes that control the awake-sleep cycles such as Bmal1 
gene and clock genes expression [dopamine regulates the Bmal1/clock activity]
• Disconnection of SCN with neuronal circuitries and hormonal signals
• SCN degeneration associated with clock gene dysregulation
• Striatum dysregulation [dopamine controlled clock proteins Per1/Per2 gene 
expression]
• Decrease rhythmic expression of retinal melanopsin [regulated by dopamine] 
that affect the entrainment of diurnal circadian rhythm
• Animal models of PD revealed changes in the neurons firing pattern of the 
SCN associated with changes in the circadian rhythm amplitude [86, 87, 103]
Light therapy is a non-invasive technique proven to be safe, well tolerated, 
and effective on the treatment of daily drowsiness and impair alertness in PD 
[104–106].
9. Diurnal sleep disorders
9.1 Excessive daytime sleepiness in PD
Excessive daytime sleepiness (EDS) involves symptoms of frequent napping, 
feeling abnormally sleepy and sleep attacks. It is seen in 33–76% of patients with 
PD [100, 107] and is likely a result of damaged to the orexin-producing neurons 
from the posterior lateral hypothalamus involved in the wakefulness [108]. Other 
brainstem stimulating monoaminergic neurons are also implicated in promoting 
wakefulness in damaged in PD [109]. EDS is common in advanced PD and is a 
marker of dopamine loss [110, 111]. Table 6 display the condition more commonly 
associated with EDS in PD.
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Sleep attacks, which are defined as sudden irresistible drowsiness without 
awareness of falling sleep, are seen in 21% of PD patients. These are particularly 
concerning as they can cause serious injuries or even death, for example, as a 
result of a car accident when the patient falls asleep while driving [45, 55]. The 
Inappropriate Sleep Composite Score (ISCS) have a high specificity to detect the 
risk of car accidents related to EDS while driving [112]. A study with drug-naïve 
patients with early PD showed that patient who developed EDS after 5 years of 
treatment had higher baseline levels of drowsiness [113].
Management of EDS includes improving sleep hygiene, daytime regular exer-
cises, avoid strenuous exercises a few hours before bedtime, reducing sedating 
medications both psychiatric (i.e. antidepressants, benzodiazepines, antipsychotics, 
etc.) as well as anti-Parkinson medications (particularly dopaminergic medications 
and levodopa), especially when used in combination [45, 114]. Stimulating anti-
Parkinson medication earlier into the day such as amantadine and selegeline may 
help with EDS and if appropriate may be used instead of DAs [115]. If above plan 
fails, consider starting stimulants such as:
• Caffeine at a dose of 200 mg twice a day [116]
• Modafanil at a dose of 100–400 mg/day [117, 118].
• Methylphenidate at a dose of 1 mg/kg TID [119]
• Sodium oxybate at a dose of 3–9 grams per night at bedtime and 4 hours 
later [120].









High comorbid disease burden
High doses of antiparkinsonian Drugs
Table 6. 
Cause of excessive daytime sleepiness in PD.




Increased slow wave sleep
Increase REM sleep
Improve insomnia
Improve restless leg syndrome
Improve daytime sleepiness
Table 7. 
Deep brain stimulation, sleep architecture and sleep disorders.
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9.2 Deep brain stimulation
Deep brain stimulation (DBS) is the most common surgical intervention for 
the treatment of PD. The procedure involves the surgical placement of electrodes, 
either unilaterally or bilaterally, in certain target areas in the brain. Most commonly 
placed in the subthalamic nucleus (STN) or the internal globus pallidus (GPi). The 
electrodes are then connected to a pulse generator implanted in the chest. DBS is 
known to improve motor symptoms and overall quality of life however we have only 
recently established that it also improves non-motor symptoms, including sleep 
[121]. STN DBS especially has shown significant improvement in sleep quality, 
sleep efficiency and sleep duration [121].
The beneficial effect on sleep architecture and sleep disorders [45] are displayed 
Table 7.
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